03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Anna Alassaad
chief strategist at the TLV, the Swedish Dental and Pharmaceutical Benefits Agency
press citation on 1 topic since 2 Jun 2026 · last quoted 2 Jun 2026
02 Quoted on · 1 of 29 topics
Anna Alassaad: key facts
- Kind of voice
- Sector leader
- Role
- chief strategist at the TLV, the Swedish Dental and Pharmaceutical Benefits Agency
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 2 Jun 2026
04 The signal · where Anna Alassaad sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Christian Gilissen, PhDAcademicprofessor of genome bioinformatics at Radboud University Medical Center1
- 25=Lisenka Vissers, PhDAcademicprofessor of translational genomics at Radboud University Medical Center1
- 25=Anna AlassaadSector leaderchief strategist at the TLV, the Swedish Dental and Pharmaceutical Benefits Agency1
- 25=Katarina AntonovSector leaderhead of analysis at LIF, the Swedish Association of Research-Based Pharmaceutical Companies1
- 25=Oskar AhlbergSector leadervice-president of Rare Disease Sweden1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Anna Alassaad has said
- euractiv.com1
Where Anna Alassaad has been quoted
- 01Swedish rare disease patients endure longer wait for new medicineseuractiv.com · 2 Jun 2026
Verbatim
“This could both be dependent on how fast manufacturers apply for a reimbursement and the agency's processing time of an application for reimbursement.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.